Earnings Summary

Fusion Pharmaceuticals Inc’s revenue jumped 1108.43% since last year same period to $2.01Mn in the Q3 2023. On a quarterly growth basis, Fusion Pharmaceuticals Inc has generated 5800% jump in its revenue since last 3-months.

Fusion Pharmaceuticals Inc’s net profit jumped 28.16% since last year same period to $-17.25Mn in the Q3 2023. On a quarterly growth basis, Fusion Pharmaceuticals Inc has generated 31.47% jump in its net profits since last 3-months.

Fusion Pharmaceuticals Inc’s net profit margin jumped 94.05% since last year same period to -860.02% in the Q3 2023. On a quarterly growth basis, Fusion Pharmaceuticals Inc has generated 98.84% jump in its net profit margins since last 3-months.

Fusion Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a 12.5% jump from last quarter’s estimates.

Fusion Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.35.

Fusion Pharmaceuticals Inc’s earning per share (EPS) jumped 54.55% since last year same period to -0.25 in the Q3 2023. This indicates that the Fusion Pharmaceuticals Inc has generated 54.55% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fusion Pharmaceuticals Inc’s return on assets (ROA) stands at -0.24.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fusion Pharmaceuticals Inc’s return on equity (ROE) stands at -0.49.